Form 10-K GALECTIN THERAPEUTICS For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Galectin Therapeutics (GALT) Tops Q4 EPS by 3c
March 15, 2016 7:43 AM EDTGalectin Therapeutics (NASDAQ: GALT) reported Q4 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22).
Management Commentary
Numerous clinical advancements during 2015 with our lead compound GR-MD-02 form the basis for a productive 2016, and we look forward to reporting on a number of important development milestones throughout the year, said Peter G. Traber, M.D., president, chief executive officer and chief medical officer of Galectin Therapeutics. Of particular note, during 2015 we began two Phase 2 studies with GR-MD-02 in non-alcoholic steatohepatitis, or NASH, a disease that has been gaining considerable awareness not only among clinicians,... More
